Literature DB >> 28993338

Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Romney M Humphries1, Janet A Hindler2, Annie Wong-Beringer3,4, Shelley A Miller2.   

Abstract

Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) MICs were evaluated for a collection of 309 beta-lactam-resistant isolates of Pseudomonas aeruginosa recovered from three institutions in the area of Los Angeles, CA. Overall, 12.0% of isolates were susceptible to imipenem, 15.9% were susceptible to meropenem, 20.7% were susceptible to piperacillin-tazobactam, 24.6% were susceptible to ceftazidime, 25.9% were susceptible to cefepime, 72.5% were susceptible to C/T, and 61.8% were susceptible to CZA. Among C/T-resistant isolates, 9.1% were CZA susceptible, whereas 36.4% of CZA-resistant isolates were susceptible to C/T.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  MIC; Pseudomonas aeruginosa; ceftazidime-avibactam; ceftolozane-tazobactam; susceptibility testing

Mesh：

Substances：

Year:  2017        PMID： 28993338      PMCID： PMC5700315          DOI： 10.1128/AAC.01858-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).

Authors:  David J Farrell; Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2014-03-26       Impact factor: 5.283

2.  Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Jose M Munita; Samuel L Aitken; William R Miller; Federico Perez; Rossana Rosa; Luis A Shimose; Paola N Lichtenberger; Lilian M Abbo; Rupali Jain; Masayuki Nigo; Audrey Wanger; Rafael Araos; Truc T Tran; Javier Adachi; Robert Rakita; Samuel Shelburne; Robert A Bonomo; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

3.  Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).

Authors:  Michael A Pfaller; Matteo Bassetti; Leonard R Duncan; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

4.  Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.

Authors:  Deanna J Buehrle; Ryan K Shields; Liang Chen; Binghua Hao; Ellen G Press; Ammar Alkrouk; Brian A Potoski; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 5.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

6.  Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013.

Authors:  S Pollett; S Miller; J Hindler; D Uslan; M Carvalho; R M Humphries
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

7.  Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).

Authors:  Helio S Sader; David J Farrell; Mariana Castanheira; Robert K Flamm; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2014-06-10       Impact factor: 5.790

8.  Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.

Authors:  Ghady Haidar; Nathan J Philips; Ryan K Shields; Daniel Snyder; Shaoji Cheng; Brian A Potoski; Yohei Doi; Binghua Hao; Ellen G Press; Vaughn S Cooper; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

9.  Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.

Authors:  Mark D Gonzalez; Allison R McMullen; Meghan A Wallace; Matthew P Crotty; David J Ritchie; Carey Ann D Burnham
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

10.  Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.

Authors:  David M Livermore; Shazad Mushtaq; Daniele Meunier; Katie L Hopkins; Robert Hill; Rachael Adkin; Aiysha Chaudhry; Rachel Pike; Peter Staves; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790
View more
  26 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

Review 2.  Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Authors:  Lynn Nguyen; Joshua Garcia; Katherine Gruenberg; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2018-06-06       Impact factor: 3.725

3.  In Vitro Susceptibility of Typhoidal, Nontyphoidal, and Extended-Spectrum-β-Lactamase-Producing Salmonella to Ceftolozane/Tazobactam.

Authors:  Jade L L Teng; Elaine Chan; Asher C H Dai; Gillian Ng; Tsz Tuen Li; Christopher Lai; Alan K L Wu; Susanna K P Lau; Patrick C Y Woo
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

4.  Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Authors:  Romney M Humphries; Janet A Hindler; Paul Magnano; Annie Wong-Beringer; Robert Tibbetts; Shelley A Miller
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

5.  Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.

Authors:  Mazen A Sid Ahmed; Hamad Abdel Hadi; Abubaker A I Hassan; Sulieman Abu Jarir; Muna A Al-Maslamani; Nahla Omer Eltai; Khalid M Dousa; Andrea M Hujer; Ali A Sultan; Bo Soderquist; Robert A Bonomo; Emad Bashir Ibrahim; Jana Jass; Ali S Omrani
Journal:  J Antimicrob Chemother       Date:  2019-12-01       Impact factor: 5.790

6.  Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.

Authors:  Fátima Galán-Sánchez; Germán Bou; Antonio Oliver; Jorge Arca-Suárez; Pablo Fraile-Ribot; Juan Carlos Vázquez-Ucha; Gabriel Cabot; Marta Martínez-Guitián; Emilio Lence; Concepción González-Bello; Alejandro Beceiro; Manuel Rodríguez-Iglesias
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

7.  Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of Pseudomonas aeruginosa Isolates.

Authors:  Christian M Gill; Tomefa E Asempa; Isabella A Tickler; Caitlin Dela Cruz; Fred C Tenover; David P Nicolau
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

8.  In vitro potency of antipseudomonal β-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals.

Authors:  Safa S Almarzoky Abuhussain; Christina A Sutherland; David P Nicolau
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

9.  Quantum Computational Investigation of (E)-1-(4-methoxyphenyl)-5-methyl-N'-(3-phenoxybenzylidene)-1H-1,2,3-triazole-4-carbohydrazide.

Authors:  Halil Gökce; Fatih Şen; Yusuf Sert; Bakr F Abdel-Wahab; Benson M Kariuki; Gamal A El-Hiti
Journal:  Molecules       Date:  2022-03-28       Impact factor: 4.411

10.  Clinical Characteristics and Resistance Patterns of Pseudomonas aeruginosa Isolated From Combat Casualties.

Authors:  Mary B Ford; Katrin Mende; Susan J Kaiser; Miriam L Beckius; Dan Lu; Jason Stam; Ping Li; Laveta Stewart; David R Tribble; Dana M Blyth
Journal:  Mil Med       Date:  2022-03-28       Impact factor: 1.563
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.